Psychometric evaluation of the EORTC QLQ-PR25 questionnaire in assessing health-related quality of life in prostate cancer survivors: a curate’s egg

详细信息    查看全文

• 作者：Eamonn O’Leary ; Frances J. Drummond ; Anna Gavin…
• 关键词：Health ; related quality of life ; Prostate cancer ; Survivors ; QLQ ; PR25
• 刊名：Quality of Life Research
• 出版年：2015
• 出版时间：September 2015
• 年：2015
• 卷：24
• 期：9
• 页码：2219-2230
• 全文大小：402 KB
• 参考文献：1.International Agency for Research on Cancer. GLOBOCAN, 2012. Fact sheets by cancer. http://?globocan.?iarc.?fr/?Pages/?fact_?sheets_?cancer.?aspx . Accessed 21 Aug 2014.
  2.Jemal, A., Center, M. M., DeSantis, C., & Ward, E. M. (2010). Global patterns of cancer incidence and mortality rates and trends. Cancer Epidemiology, Biomarkers and Prevention, 19(8), 1893-907.PubMed View Article
  3.De Angelis, R., Sant, M., Coleman, M. P., Francisci, S., Baili, P., Pierannunzio, D., et al. (2014). Cancer survival in Europe 1999-007 by country and age: Results of EUROCARE-5—a population-based study. The lancet Oncology, 15(1), 23-4.PubMed View Article
  4.Siegel, R., DeSantis, C., Virgo, K., Stein, K., Mariotto, A., Smith, T., et al. (2012). Cancer treatment and survivorship statistics, 2012. CA: A Cancer Journal for Clinicians, 62(4), 220-41.
  5.Sharp, L., Deady, S., Gallagher, P., Molcho, M., Pearce, A., Thomas, A. A., Timmons, A., & Comber, H. (2014). The magnitude and characteristics of the population of cancer survivors: Using population-based estimates of cancer prevalence to inform service planning for survivorship care. BMC Cancer, 14(1), 767.
  6.Bray, F., Ren, J.-S., Masuyer, E., & Ferlay, J. (2013). Global estimates of cancer prevalence for 27 sites in the adult population in 2008. International Journal of Cancer, 132(5), 1133-145.View Article
  7.Rnic, K., Linden, W., Tudor, I., Pullmer, R., & Vodermaier, A. (2013). Measuring symptoms in localized prostate cancer: A systematic review of assessment instruments. Prostate Cancer and Prostatic Diseases, 16(2), 111-22.PubMed
  8.Van Andel, G., Bottomley, A., Foss?, S. D., Efficace, F., Coens, C., Guerif, S., et al. (2008). An international field study of the EORTC QLQ-PR25: A questionnaire for assessing the health-related quality of life of patients with prostate cancer. European Journal of Cancer, 44(16), 2418-424.PubMed View Article
  9.Arraras, J. I., Villafranca, E., Arias de la Vega, F., Romero, P., Rico, M., Vila, M., et al. (2009). The EORTC Quality of Life Questionnaire for patients with prostate cancer: EORTC QLQ-PR25. Validation study for Spanish patients. Clinical and Translational Oncology, 11(3), 160-64.PubMed View Article
  10.Chie, W.-C., Yu, C.-C., & Yu, H.-J. (2010). Reliability and validity of the Taiwan Chinese version of the EORTC QLQ-PR25 in assessing quality of life of prostate cancer patients. Urological Science, 21(3), 118-25.View Article
  11.Chang, Y.-J., Liang, W.-M., Wu, H.-C., Lin, H.-C., Wang, J.-Y., Li, T.-C., et al. (2012). Psychometric evaluation of the Taiwan Chinese version of the EORTC QLQ-PR25 for HRQOL assessment in prostate cancer patients. Health and Quality of Life Outcomes, 10(1), 96.PubMed Central PubMed View Article
  12.Park, J., Shin, D. W., Yun, S. J., Park, S.-W., Jeon, S. S., Kwak, C., et al. (2013). Cross-cultural application of the Korean version of the European Organization for Research and Treatment of Cancer quality of life questionnaire for patients with prostate cancer-EORTC QLQ-PR25. Oncology, 85(5), 299-05.PubMed View Article
  13.Denham, J. W., Wilcox, C., Lamb, D. S., Spry, N. A., Duchesne, G., Atkinson, C., et al. (2012). Rectal and urinary dysfunction in the TROG 03.04 RADAR trial for locally advanced prostate cancer. Radiotherapy and Oncology, 105(2), 184-92.PubMed View Article
  14.Drummond, F.J., Kinnear, H., O’Leary, E., Donnelly, Gavin, A., & Sharp, L. (2015). Long-term health related quality of life of prostate cancer survivors varies by primary treatment. Results from the PiCTure (Prostate Cancer Treatment, your experience) study. Journal of Cancer Survivorship: Research and Practice. doi:10.-007/?s11764-014-0419-6 .
  15.Selli, C., Bjartell, A., Burgos, J., Somerville, M., Palacios, J.-M., Benjamin, L., et al. (2014). Burden of illness in prostate cancer patients with a low-to-moderate risk of progression: A one-year, pan-European observational study. Prostate Cancer, 2014, 1-.View Article
  16.Macmillan Cancer Support. Living with or beyond cancer. http://?www.?macmillan.?org.?uk/?GetInvolved/?Campaigns/?Weareaforceforch?ange/?Survivorship/?Livingwithorbeyo?ndcancer.?aspx . Accessed 02 Feb 2015.
  17.Aaronson, N. K., Ahmedzai, S., Bergman, B., Bullinger, M., Cull, A., Duez, N. J., et al. (1993). The European Organization for Research and Treatment of Cancer QLQ-C30: A quality-of-life instrument for use in international clinical trials in oncology. Journal of the National Cancer Institute, 85(5), 365-76.PubMed View Article
  18.Lovibond, S. H., & Lovibond, P. F. (1995). Manual for the depression anxiety stress scales (2nd ed.). Sydney: Psychology Foundation.
  19.EuroQol Group. (1990). EuroQol–a new facility for the measurement of health-related quality of life. Health Policy, 16(3), 199-08.View Article
  20.Oemar, M., & Janssen, B. (2013). EQ-5D-5L user guide. Rotterdam: EuroQoL Group.
  21.Brooks, R. (1996). EuroQol: The current state of pl
• 作者单位：Eamonn O’Leary (1)
  Frances J. Drummond (1)
  Anna Gavin (2)
  Heather Kinnear (2)
  Linda Sharp (1) (3)
  
  1. National Cancer Registry, Cork, Ireland
  2. Northern Ireland Cancer Registry, Belfast, UK
  3. Institute of Health and Society, Newcastle University, Baddiley-Clark Building, Richmond Road, Newcastle upon Tyne, NE2 4AX, UK
  
• 刊物类别：Medicine
• 刊物主题：Medicine & Public Health
  Quality of Life Research
  Sociology
  Public Health
  
• 出版者：Springer Netherlands
• ISSN：1573-2649

文摘

Purpose The EORTC QLQ-PR25 was primarily developed to measure disease-specific health-related quality of life (HRQoL) of prostate cancer (PCa) patients undergoing active treatment. The growing number of cancer survivors has focussed interest on assessing survivors-HRQoL. We evaluated psychometric properties of the EORTC QLQ-PR25 questionnaire amongst PCa survivors. Methods A postal questionnaire, including the QLQ-PR25, was administered to 6559 PCa survivors 2-8?years post-diagnosis, identified through population-based cancer registries in Ireland; 3348 participated. The QLQ-PR25 has been suggested to have five multi-item subscales measuring urinary (US), bowel (BS) and hormone treatment-related symptoms (TS), sexual activity (SA) and sexual functioning (SF), and a single item measuring bother due to using incontinence aids (IA). Reliability analysis, divergent validity, discriminant validity (compared to EORTC QLQ-C30, DASS-21 and EuroQoL EQ-5D-5L), and exploratory and confirmatory factor analysis (EFA, CFA) were undertaken. Results The percentage of survivors completing QLQ-PR25 subscales was: US-79?%; IA-20?%; BS-83?%; TS-86?%; SA-87?%; and SF-26?%. Reliability was acceptable (Cronbach’s α?>?0.7) for three subscales (US, SA, SF). The instrument discriminated well between clinically distinct groups, especially those defined by primary treatment(s) and stage at diagnosis. The SA and SF subscales showed good discriminant validity compared to QLQ-C30, DASS-21 and EQ-5D-5L; other subscales did not. EFA reproduced a near fit to the proposed factor structure. CFA confirmed this. Conclusion This is the largest ever QLQ-PR25 validation study. When used in PCa survivors, although the proposed factor structure was confirmed, some of the subscales (e.g. BS and TS) showed poor reliability, a lack of discriminant validity and moderate levels of item non-response.